Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000
Sign Up to like & getrecommendations! Published in 2018 at "Cancer"
DOI: 10.1002/cncr.31370
Abstract: The prognosis is poor for patients who have relapsed‐refractory acute myelogenous leukemia (AML). Most published reports analyzed results from therapies in first‐salvage AML or in studies that were conducted before 2000. Several novel agents and… read more here.
Keywords: since 2000; results second; myelogenous leukemia; second salvage ... See more keywords
BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study
Sign Up to like & getrecommendations! Published in 2020 at "Cancer"
DOI: 10.1002/cncr.33338
Abstract: CXCR4 mediates the retention and survival of acute myelogenous leukemia blasts in bone marrow and contributes to their resistance to chemotherapy. The authors evaluated a combination of the high‐affinity CXCR4 antagonist BL‐8040 with high‐dose cytarabine… read more here.
Keywords: relapsed refractory; cxcr4 antagonist; myelogenous leukemia; phase study ... See more keywords
Effects of Neddylation and mTOR Inhibition in Acute Myelogenous Leukemia
Sign Up to like & getrecommendations! Published in 2019 at "Translational Oncology"
DOI: 10.1016/j.tranon.2019.01.001
Abstract: Acute myelogenous leukemia (AML) is a heterogeneous disease and often relapses after standard chemotherapy. Recently, the neddylation (NEDD8) and the mammalian target of rapamycin (mTOR) signaling pathways have emerged as promising pharmaceutical targets for AML… read more here.
Keywords: acute myelogenous; inhibition; neddylation; mtor ... See more keywords
Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen.
Sign Up to like & getrecommendations! Published in 2019 at "Experimental cell research"
DOI: 10.1016/j.yexcr.2019.05.021
Abstract: Acute myelogenous leukemia (AML) is a hematological malignancy marked by the accumulation of large numbers of immature myeloblasts in bone marrow. The overall prognosis in AML is poor; hence, there is a pressing need to… read more here.
Keywords: drug regimen; myelogenous leukemia; pivotal role; ceramide tamoxifen ... See more keywords
A STEMI MIMIC: MYOCARDIAL INVASION BY THE ACUTE MYELOGENOUS LEUKEMIA
Sign Up to like & getrecommendations! Published in 2020 at "Journal of the American College of Cardiology"
DOI: 10.1016/s0735-1097(20)33078-3
Abstract: Secondary cardiac cancer commonly occurs via metastatic spread into pericardium and myocardium from primary neoplastic process. ST segment elevation can mimic acute coronary syndrome despite absence of coronary obstruction. A 33-year old male with history… read more here.
Keywords: mimic myocardial; invasion acute; stemi mimic; myelogenous leukemia ... See more keywords
N-Heterocyclic 3-Pyridyl Carboxamide Inhibitors of DHODH for the Treatment of Acute Myelogenous Leukemia.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c00788
Abstract: Acute myelogenous leukemia (AML), a disease of the blood and bone marrow, is characterized by the inability of myeloblasts to differentiate into mature cell types. Dihydroorotate dehydrogenase (DHODH) is an enzyme well-known in the pyrimidine… read more here.
Keywords: myelogenous leukemia; acute myelogenous; pyridyl carboxamide; dhodh ... See more keywords
Identification of Pyrrolo[2,3- d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.9b00223
Abstract: A series of pyrrolo[2,3- d]pyrimidine derivatives were prepared and optimized for cytotoxic activities against FLT3-ITD mutant cancer cells. Among them, compound 9u possessed nanomolar FLT3 inhibitory activities and subnanomolar inhibitory activities against MV4-11 and Molm-13… read more here.
Keywords: treating acute; pyrrolo pyrimidine; kinase; myelogenous leukemia ... See more keywords
Diagnosis and relapse: cytogenetically normal acute myelogenous leukemia without FLT3-ITD or MLL-PTD
Sign Up to like & getrecommendations! Published in 2017 at "Leukemia"
DOI: 10.1038/leu.2016.343
Abstract: Diagnosis and relapse: cytogenetically normal acute myelogenous leukemia without FLT3 -ITD or MLL -PTD read more here.
Keywords: normal acute; acute myelogenous; cytogenetically normal; relapse cytogenetically ... See more keywords
LncRNA SNHG5 upregulation induced by YY1 contributes to angiogenesis via miR-26b/CTGF/VEGFA axis in acute myelogenous leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Laboratory Investigation"
DOI: 10.1038/s41374-020-00519-9
Abstract: Acute myelogenous leukemia (AML) is the most common acute leukemia in adults. Despite great progress has been made in this field, the pathogenesis of AML is still not fully understood. We report here the biological… read more here.
Keywords: myelogenous leukemia; mir 26b; aml; acute myelogenous ... See more keywords
Core binding factor acute myelogenous leukemia-2021 treatment algorithm
Sign Up to like & getrecommendations! Published in 2021 at "Blood Cancer Journal"
DOI: 10.1038/s41408-021-00503-6
Abstract: Core binding factor acute myelogenous leukemia (CBF-AML), characterized by the presence of either t(8;21) (q22;q22) or inv(16) (p13q22)/t(16;16), is considered good-risk AML in the context of cytarabine based intensive chemotherapy. Still, outcome can be improved… read more here.
Keywords: factor acute; binding factor; myelogenous leukemia; core binding ... See more keywords
A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia
Sign Up to like & getrecommendations! Published in 2019 at "Nature biomedical engineering"
DOI: 10.1038/s41551-019-0387-2
Abstract: Acute myelogenous leukaemia (AML) is associated with risk factors that are largely unknown and with a heterogeneous response to treatment. Here, we provide a comprehensive quantitative understanding of AML proteomic heterogeneities and hallmarks by using… read more here.
Keywords: myelogenous leukaemia; heterogeneities hallmarks; analysis; leukaemia cell ... See more keywords